erbB in NSCLC as a molecular target: current evidences and future directions

ESMO Open

article

Marzia Del Re¹  Federico Cucchiara¹  Iacopo Petrini²  Stefano Fogli¹  Antonio Passaro³  Stefania Crucitta¹  Ilaria Attili³  Filippo De Marinis³  Antonio Chella²  Romano Danesi¹ 

[1] Clinical and Experimental Medicine, University Hospital of Pisa;Translational Research and New Technologies in Medicine, University Hospital of Pisa;Division of Thoracic Oncology, European Institute of Oncology - IRCCS

关键词: NSCLC;    erbB;    TKIs;    liquid biopsy;    radiomics;   

DOI  :  10.1136/esmoopen-2020-000724

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

A number of treatments have been developed for HER1, 2 and 3-driven non-small cell lung cancer (NSCLC), of which the most successful have been the epidermal growth factor receptor-tyrosine kinase inhibitors in HER1-mutant tumours resulting in highly improved progression-free survival. Human epidermal growth factor (HER)2 and 3-driven tumours represent the minority of NSCLC, and effective therapies in these patients still represent an unmet medical need. The encouraging results seen with anti-HER2 and anti-HER3 monoclonal antibodies need to be validated in larger studies, even if the greatest obstacle is represented by the exiguous number of patients bearing deregulated HER2/3 system and abnormalities of signal transduction pathway. Considering NSCLC tumour heterogeneity, which affects response and resistance to treatment, combined multiparametric approaches, such as liquid biopsy together with radiomics, may provide a better understanding of the tumour dynamics and clonal selection during the treatments.

【 授权许可】

CC BY|CC BY-NC-ND